Alzheimer's Treatment in Cuba: NeuralCIM® Therapy & Neurorestoration

Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia worldwide, accounting for 60–80% of all dementia cases. It is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tau tangles in the brain, leading to synaptic loss, neuronal death, and progressive cognitive decline.

In Cuba, Alzheimer's treatment is approached through a unique combination of biotechnology and intensive neurorehabilitation. The Center for Molecular Immunology (CIM) and the International Center for Neurological Restoration (CIREN) have collaborated to develop NeuralCIM®, a neuroprotective therapy that aims to slow disease progression and improve quality of life for patients with mild-to-moderate Alzheimer's disease.

Cuba's approach integrates pharmacological treatment, cognitive rehabilitation, physical therapy, and family support into a single coordinated program — a model that has attracted international patients from over 40 countries seeking alternatives not available in their home healthcare systems.

Early-stage Alzheimer's disease often presents with subtle cognitive changes that may be mistaken for normal aging. Common early signs include difficulty remembering recent conversations or events, repeating questions, misplacing items in unusual locations, and struggling to find the right word during conversations.

As the disease progresses, symptoms expand to include disorientation in time and place, difficulty with problem-solving and planning, withdrawal from work or social activities, mood changes such as increased anxiety or suspicion, and difficulty completing familiar tasks such as cooking or managing finances.

Family members are often the first to notice these changes. If you or a loved one are experiencing persistent memory problems or cognitive changes, an early medical evaluation is essential — early intervention can help preserve cognitive function for longer and allows patients to participate in treatment decisions.

Diagnosing Alzheimer's disease requires a comprehensive medical evaluation. At CIREN, the diagnostic protocol includes a detailed clinical history, cognitive assessment using standardized scales (MMSE, MoCA), neuropsychological testing, brain imaging (MRI, PET), and laboratory tests to rule out reversible causes of cognitive decline.

CIREN's diagnostic process is among the most thorough available internationally. It typically involves a multidisciplinary team of neurologists, neuropsychologists, psychiatrists, and rehabilitation specialists who jointly evaluate each patient to build a comprehensive clinical picture before recommending a treatment plan.

Advanced neuroimaging — including MRI volumetry to assess hippocampal atrophy and PET imaging for amyloid and tau pathology — provides objective biomarkers that support an accurate diagnosis and help track disease progression over time.

Alzheimer's disease is generally classified into three main stages: mild (early), moderate (middle), and severe (late). In the mild stage, patients retain much of their independence but may experience memory lapses and difficulty with complex tasks. The moderate stage brings more pronounced cognitive decline, requiring increasing assistance with daily activities. In the severe stage, patients lose the ability to respond to their environment and require full-time care.

Cuba's NeuralCIM® therapy and CIREN rehabilitation programs are most effective for patients in the mild-to-moderate stages. Early intervention is critical — patients who begin treatment earlier in the disease trajectory tend to achieve better outcomes in terms of cognitive preservation and quality of life.

Each patient's stage is determined through comprehensive assessment at CIREN, and the treatment program is individualized based on disease stage, cognitive profile, physical condition, and personal goals.

NeuralCIM® is a neuroprotective therapy developed by Cuba's Center for Molecular Immunology (CIM). It is designed to protect neurons from degeneration, reduce neuroinflammation, and support synaptic function. The therapy is administered as part of a comprehensive program at CIREN that combines the biotechnological treatment with intensive cognitive rehabilitation, physical therapy, and occupational therapy.

The CIREN program for Alzheimer's patients typically runs 4–8 weeks and includes 4–6 hours of daily therapy across multiple disciplines. This intensive, coordinated model is distinctive to the Cuban approach and is designed to maximize neuroplasticity and functional improvement.

Patients receive a personalized treatment plan based on their diagnosis, disease stage, and functional assessment. The program includes regular monitoring by neurologists, neuropsychological reassessment, and adjustments to the therapy protocol as needed throughout the treatment period.

NeuralCIM® therapy and the CIREN rehabilitation program are indicated for patients with mild-to-moderate Alzheimer's disease who meet clinical criteria. Eligibility is determined through review of the patient's medical history, neuroimaging, cognitive assessment scores, and overall health status.

Patients with severe-stage Alzheimer's, significant comorbidities, or contraindications identified during medical review may not be suitable candidates. Each case is evaluated individually by the CIREN medical team, and a formal recommendation is provided after comprehensive assessment.

To begin the eligibility review, patients or their family members should submit recent medical records including brain MRI, neurologist's report, cognitive assessment results, and current medication list through our international patient services portal.

International patients traveling to Cuba for Alzheimer's treatment receive comprehensive logistical support from SMC Salud's international patient services team. This includes medical visa assistance, airport reception, accommodation arrangements near CIREN for patients and family members, translation services, and all in-country transportation.

Treatment costs vary based on the individualized program duration, therapy intensity, and specific medical needs. A detailed cost estimate is provided after the medical review process. The program typically includes all medical consultations, therapy sessions, diagnostic tests, medications, accommodation, and ground transportation.

Family members are encouraged to accompany patients, and SMC Salud coordinates all arrangements including family accommodation, meals, cultural activities, and support services throughout the treatment period.